2023
MULTI-ANCESTRY META-ANALYSIS OF TOBACCO USE DISORDERS PRIORITIZES NOVEL CANDIDATE RISK GENES AND REVEALS ASSOCIATIONS WITH NUMEROUS HEALTH OUTCOMES
Sanchez-Roige S, Toikumo S, Jennings M, Pham B, Lee H, Mallard T, Bianchi S, Meredith J, Smoller J, Davis L, Justice A, Kranzler H, Kember R, Sanchez-Roige S. MULTI-ANCESTRY META-ANALYSIS OF TOBACCO USE DISORDERS PRIORITIZES NOVEL CANDIDATE RISK GENES AND REVEALS ASSOCIATIONS WITH NUMEROUS HEALTH OUTCOMES. European Neuropsychopharmacology 2023, 75: s8-s9. DOI: 10.1016/j.euroneuro.2023.08.024.Peer-Reviewed Original ResearchTobacco use disorderUse disordersPrevalent substance use disordersSubstance use disordersRisk genesNumerous health outcomesHIV infectionHeart diseaseSmoking behaviorMedical outcomesGenome-wide association studiesNicotine consumptionHealth outcomesCandidate risk genesPotential risk genesGenetic factorsIndependent risk lociDisordersRisk variantsNovel candidate risk genesRisk lociOutcomesMajority of variantsFunctional genomics toolsPsychiatric traits
2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisorders